Archives of Gynecology and Obstetrics

, Volume 244, Issue 1, pp 15–21 | Cite as

Combination chemotherapy with epirubicin and cisplatin in ovarian carcinoma

  • L. C. Fuith
  • A. Bazzanella
  • H. Hetzel


Combination chemotherapy with epirubicin-cisplatin was employed after surgical treatment in 67 women with ovarian carcinoma. 50 mg/m2 of epirubicin and cisplatin each were administered at monthly intervals. The response rate was correlated with the clinical stage and the residual disease. Tumor regression (CR+PR) was observed in 63.6% of patients with stage III disease, and in 50% of those with stage IV disease. Furthermore, complete or partial responses were obtained in 86.4% of patients with a residual deposit of 2–5 cm, and in 33.3% of women with a residual deposit exceeding 5 cm in diameter. Anemia occurred in 47.8%, leukopenia in 43.3%, and thrombocytopenia in 4.5% of the patients. No cardiotoxicity was recorded.

Key words

Epirubicin Cisplatin Combination chemotherapy Ovarian carcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Anteby SO, Mor Yosef S, Scheuker JG (1983) Ovarian cancer — geographical, host and environmental factors. Arch Gynecol 234:137–148Google Scholar
  2. 2.
    Young RC, De Vita VT (1974) The design of clinical trials in the therapy of ovarian carcinoma. Am J Obstet Gynecol 120:1012–1024Google Scholar
  3. 3.
    Bruckner HW, Cohen CJ, Goldberg JD, Kabakow B, Wallach RC, Deppe G, Greenspan EM, Gusberg SM, Holland JF (1981) Improved chemotherapy for ovarian cancer with Cis-diamminedichloroplatinum and adriamycin. Cancer 47:2288–2294Google Scholar
  4. 4.
    Trope C (1984) In: Bonadonna G (ed) Advances in anthracycline chemotherapy epirubicin. Masson, Milano, pp 91–93Google Scholar
  5. 5.
    Kottmeier HL (1971) Report presented by the Cancer Commitee to the General Assembly of F.I.G.O., New York 1970Google Scholar
  6. 6.
    Barber HRK, Sommers SG, Snyder R, Kwon TH (1975) Histological and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 121:795–807Google Scholar
  7. 7.
    Kaplan EL, Meier P (1958) Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457–481Google Scholar
  8. 8.
    World Health Organization (1979) Handbook for reporting results of cancer treatment. Wld Hlth Org offset publication No. 48Google Scholar
  9. 9.
    Shelley WE, Carmichael JC, Brown LB, Fraser RC, Kirk ME, Krepart GV, Levitt M, Roy M, Willan AR, Wilson KS (1988) Adriamycin and cisplatin in the treatment of stage III and IV epithelial ovarian carcinoma. Gynecol Oncol 29:208–221Google Scholar
  10. 10.
    Lefrac EA, Pitha J, Rosenheim S, Ottlieb GA (1973) A clinical pathologic analysis of adriamycin cardiotoxicity. Cancer 32:302–314Google Scholar
  11. 11.
    Guthrie D, Gibson AL (1977) Doxorubicin cardiotoxicity: possible role of digoxin in its prevention. Br Med J 2:1447–1449Google Scholar
  12. 12.
    Ganzina F (1983) 4′-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev 10:1–22Google Scholar
  13. 13.
    Eckhardt S, Cerar O, Chylak V, Hernadi Z, Hindy I, József S, Juhos E, Kolaric K, Kopecny J, Koza I, Mechl Z, Miksics K, Németh L, Pawlicki M, Plesnicar S, Ploch E, Schoket Z, Stepanek Z, Svancarova L, Vizhányó T, Zuchovska B (1987) Activity of epirubicin in combination chemotherapy of advanced ovarian cancer Oncology 44:69–72Google Scholar

Copyright information

© Springer-Verlag 1988

Authors and Affiliations

  • L. C. Fuith
    • 1
  • A. Bazzanella
    • 1
  • H. Hetzel
    • 1
  1. 1.Department of Obstetrics and GynecologyUniversity of InnsbruckInnsbruckAustria

Personalised recommendations